<DOC>
	<DOCNO>NCT00979875</DOCNO>
	<brief_summary>This single-center , Phase 1 , randomize , double-blind , 6-way crossover study determine insulin pharmacokinetics , insulin glucodynamics , safety , tolerability subcutaneously administer dose ( ) insulin lispro + recombinant human hyaluronidase PH20 ( rHuPH20 ) , insulin lispro alone , insulin glulisine + rHuPH20 , insulin glulisine alone , insulin aspart + rHuPH20 , insulin aspart alone .</brief_summary>
	<brief_title>A Pharmacokinetic Glucodynamic Study Subcutaneously Administered Insulin Analogs With rHuPH20 Compared Insulin Analogs Alone</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Healthy participant age 18 55 year , inclusive ( healthy define clinically relevant abnormality ) . Body mass index ( BMI ) 1827 kilogram per meter square ( kg/m^2 ) , inclusive . Total body weight &gt; 65 kilogram ( kg ) ( 143 pound [ lb ] ) men &gt; 46 kg ( 101 lb ) woman . Decision make capacity willingness comply schedule visit , treatment plan , laboratory test , study procedure include adequate venous access . Vital sign ( blood pressure [ BP ] , pulse rate , body temperature ) within normal range , range , assess Principal Investigator clinically significant . Fasting blood glucose level &lt; 100 milligram per deciliter ( mg/dL ) screening . A negative serum pregnancy test ( female childbearing potential ) . Female participant childbearing potential must agree practice effective birth control abstinence currently agree continue duration time study . Signed , write institutional review board ( IRB ) approve informed consent . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , oncologic , neurologic ( include history seizure ) disease ; hypoglycemic episode ; intercurrent illness ( influenza ) ; allergic disease ( include severe drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Clinical significance determine Principal Investigator . As judged investigator , clinically significant finding routine laboratory data . ( Anemia hematocrit less 33 % screen specifically exclusionary . ) Known history diabetes mellitus ( type 1 type 2 ) gestational diabetes . Known allergy hyaluronidase ingredient study drug . Positive human immunodeficiency virus ( HIV ) 1 , hepatitis B , hepatitis C antibody test . History evidence alcohol drug abuse . History evidence use tobacco nicotinecontaining product within 6 month prior screen screen qualitative urine nicotine test . Use drug may interfere interpretation study result know cause clinically relevant interference insulin action glucose utilization . Blood donation high volume phlebotomy , example , &gt; 100 milliliter ( mL ) , within 56 day dose . Participation study investigational drug device 30 day enrollment study . The participant unfit study opinion investigator . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>insulin</keyword>
	<keyword>recombinant human hyaluronidase</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>